Skip to main content
Watch Insiders

Corporate insider profile

Jean Jacques Bienaime Insider Trades

Latest reported as Director of Keros Therapeutics, Inc. (KROS).

Purchase filings
10
Reported companies
3
Net open-market value
$1,264,267
Latest transaction
Aug 17, 2026

Affiliated corporations

Reported company relationships

KROSLatest reported

Keros Therapeutics, Inc.

Director

ASNDPrior filing

Ascendis Pharma A/S

Director

IMNMPrior filing

Immunome Inc.

Director

Transaction history

Open-market Transactions

Open-market insider purchase and sale transactions
DateCompanyRoleTypeSharesPriceTotal value
Aug 17, 2026Keros Therapeutics, Inc. (KROS)DirectorOpen Market Purchase1,000$10.27$10,270
Aug 14, 2026Ascendis Pharma A/S (ASND)DirectorOpen Market Purchase2,000$246.33$492,654
Jul 15, 2026Keros Therapeutics, Inc. (KROS)DirectorOpen Market Purchase1,000$10.61$10,610
Jun 15, 2026Keros Therapeutics, Inc. (KROS)DirectorOpen Market Purchase1,000$10.19$10,190
Jun 5, 2026Immunome Inc. (IMNM)DirectorOpen Market Purchase21,000$19.43$408,080
May 29, 2026Ascendis Pharma A/S (ASND)DirectorOpen Market Purchase500$223.12$111,562
May 26, 2026Ascendis Pharma A/S (ASND)DirectorOpen Market Purchase400$237.80$95,121
May 15, 2026Keros Therapeutics, Inc. (KROS)DirectorOpen Market Purchase1,000$10.58$10,580
May 15, 2026Immunome Inc. (IMNM)DirectorOpen Market Purchase5,000$20.70$103,500
Apr 15, 2026Keros Therapeutics, Inc. (KROS)DirectorOpen Market Purchase1,000$11.70$11,700